Research of all three scientists from the CEITEC programme Molecular medicine is focused on the study of genetic modifications that lead to different types of leukemia. Awarded publication presents result of many years effort to study the role of tumour suppressor in leukemia cells that at the end lead to new exciting findings about P53 oncogene. It has been shown that patients with chronic lymphocytic leukemia (CLL) with defects in TP53 gene have significantly worse prognosis, poor response and reduced overall survival with standard treatment approaches.
Thanks to long-term collaboration with European research initiative for CLL (ERIC) Prof. Sarka Pospisilova started this international initiative to establish recommendations for researchers and clinicians on how, when and in which patients to perform the mutational analyses of P53 oncogene. These recommendations have direct impact in clinical practice, significantly improve prognosis and diagnosis of the patients with chronic lymphocytic leukemia and enable application of more effective personalized therapy.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012 Jul;26(7):1458-61
